PHARMACOKINETIC (PK) PROFILE OF LIPOSOMAL AMIKACIN FOR INHALATION (LAI) IN PATIENTS WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA INFECTION

被引：0
作者：
Clancy, J. P. [1 ]
Konstan, M. [1 ]
Fajac, I [1 ]
Pressler, T. [1 ]
Sands, D. [1 ]
Minic, P. [1 ]
Cipolli, M. [1 ]
Bilton, D. [2 ]
Eagle, G. [3 ]
McGinnis, J. [3 ]
Monroe, R. [3 ]
Rubino, C. [4 ]
机构：
[1] CF LAI Study Grp, Bridgewater, NJ USA
[2] Royal Brompton Hosp, London SW3 6LY, England
[3] Insmed Inc, Bridgewater, NJ USA
[4] Inst Clin Pharmacodynam, Latham, NY USA
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
444
引用
收藏
页码：358 / 359
页数：2
相关论文
共 50 条
  • [41] Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF)
    Caskey, S.
    Stirling, J.
    Moore, J. E.
    Rendall, J. C.
    LETTERS IN APPLIED MICROBIOLOGY, 2018, 66 (06) : 537 - 541
  • [42] Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Daniel Conole
    Gillian M. Keating
    Drugs, 2014, 74 : 377 - 387
  • [43] Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Conole, Daniel
    Keating, Gillian M.
    DRUGS, 2014, 74 (03) : 377 - 387
  • [44] Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis
    Greally, Peter
    Whitaker, Paul
    Peckham, Daniel
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (06) : 1059 - 1067
  • [45] A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    Retsch-Bogart, George Z.
    Burns, Jane L.
    Otto, Kelly L.
    Liou, Theodore G.
    McCoy, Karen
    Oermann, Christopher
    Gibson, Ronald L.
    PEDIATRIC PULMONOLOGY, 2008, 43 (01) : 47 - 58
  • [46] Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis
    Parkins, Michael D.
    Elborn, J. Stuart
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (05) : 609 - 622
  • [47] A Randomized Placebo-Controlled Study of Nebulized Liposomal Amikacin (Arikace™) in the Treatment of Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Lung Infection (Protocol TR02-105).
    Gupta, R.
    Dupont, L.
    Minic, P.
    Fustik, S.
    Mazurek, H.
    Solyom, E.
    Feketeova, A.
    Csiszer, E.
    Okusanya, O.
    Quittner, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [48] Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
    Lam, John
    Vaughan, Steven
    Parkins, Michael D.
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2013, 7 : 61 - 77
  • [49] Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis
    Almeida, Mila M.
    Freitas, Meyvianne T.
    Folescu, Tania W.
    Firmida, Monica C.
    Carvalho-Assef, Ana Paula D'A.
    Marques, Elizabeth A.
    Leao, Robson S.
    CURRENT MICROBIOLOGY, 2021, 78 (02) : 696 - 704
  • [50] Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis
    Mila M. Almeida
    Meyvianne T. Freitas
    Tania W. Folescu
    Monica C. Firmida
    Ana Paula D’A. Carvalho-Assef
    Elizabeth A. Marques
    Robson S. Leão
    Current Microbiology, 2021, 78 : 696 - 704
12345